These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 25060490)

  • 21. The conquest of melanoma by immunotherapy.
    Lejeune FJ
    Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunotherapy and the concept of a clinical cure.
    Eggermont AM; Kroemer G; Zitvogel L
    Eur J Cancer; 2013 Sep; 49(14):2965-7. PubMed ID: 23890942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
    Melis C; Rogiers A; Bechter O; van den Oord JJ
    Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
    Barker CA; Postow MA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):986-97. PubMed ID: 24661650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
    Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
    J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous Melanoma - A Review of Systemic Therapies.
    Lee KA; Nathan P
    Acta Derm Venereol; 2020 Jun; 100(11):adv00141. PubMed ID: 32346745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combinatorial approach to treatment of melanoma.
    Ashworth MT; Daud AI
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):601-12. PubMed ID: 24880950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant use of ipilimumab in locally advanced melanoma.
    Howie LJ; Tyler DS; Salama AK
    J Surg Oncol; 2015 Dec; 112(8):841-3. PubMed ID: 26768512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
    Roszik J; Haydu LE; Hess KR; Oba J; Joon AY; Siroy AE; Karpinets TV; Stingo FC; Baladandayuthapani V; Tetzlaff MT; Wargo JA; Chen K; Forget MA; Haymaker CL; Chen JQ; Meric-Bernstam F; Eterovic AK; Shaw KR; Mills GB; Gershenwald JE; Radvanyi LG; Hwu P; Futreal PA; Gibbons DL; Lazar AJ; Bernatchez C; Davies MA; Woodman SE
    BMC Med; 2016 Oct; 14(1):168. PubMed ID: 27776519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Betting on immunotherapy for melanoma.
    Sznol M
    Curr Oncol Rep; 2009 Sep; 11(5):397-404. PubMed ID: 19679015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
    Michielin O; Hoeller C
    Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newer developments in the immunotherapy of malignant melanoma.
    Maslin B; Alexandrescu DT; Ichim TE; Dasanu CA
    J Oncol Pharm Pract; 2014 Feb; 20(1):3-10. PubMed ID: 23435643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.
    Silva IP; Long GV
    Curr Opin Oncol; 2017 Nov; 29(6):484-492. PubMed ID: 28914644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.